CYP3A4 and prostate carcinoma: Additionally, W. somnifera is an inducer of CYP3A4 which is involved in metabolism of several standard treatments for prostate cancer, such as relugolix.27 How the combination of W. somnifera and conventional prostate cancer treatments can affect the response to treatment needs to be determined at different levels, including through clinical studies.